Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Maury Raycroft has upgraded BioCryst Pharma (NASDAQ:BCRX) from Hold to Buy and set a price target of $11.
August 04, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharma has been upgraded to Buy from Hold by Jefferies with a price target of $11.
The upgrade from Hold to Buy by Jefferies indicates a positive outlook for BioCryst Pharma. The price target of $11 suggests that the analyst sees potential for the stock's price to increase. This could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100